December 08, 2020
Chimeric antigen receptor T-cell therapy with lisocabtagene maraleucel led to rapid and durable responses in patients with high-risk relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
December 07, 2020
The combination of umbralisib plus ublituximab plus venetoclax demonstrated encouraging efficacy as treatment of patients with relapsed/refractory chronic lymphocytic leukemia, including those who are refractory to prior therapy with a Bruton tyrosine kinase inhibitor.
December 07, 2020
In the phase 3 UNITY-CLL study, ublituximab in combination with umbralisib demonstrated synergistic activity in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy irrespective of prior treatment.
December 07, 2020
Jennifer R. Brown, MD, PhD, discusses the implications of the findings from a pooled analysis of cardiovascular events from studies of the next-generation BTK inhibitor acalabrutinib monotherapy as treatment of patients with chronic lymphocytic leukemia.
December 05, 2020
Sustained progression-free survival and overall survival benefit at 5 years were observed in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia treated with the combination of venetoclax plus rituximab compared with bendamustine plus rituximab in the MURANO trial.
December 05, 2020
Placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
December 01, 2020
A rolling submission of a Biologics License Application to the FDA has been initiated for the combination of ublituximab plus umbralisib as treatment of patients with chronic lymphocytic leukemia .
November 23, 2020
During a Targeted Oncology Case Based Peer Perspective event, Erlene Seymour, MD, reviewed the front-line treatment options for chronic lymphocytic leukemia.
November 15, 2020
During a Targeted Oncology Case Based Peer Perspectives event, Farrukh Awan, MD, discussed the various treatment options for a 61-year-old patient with high-risk chronic lymphocytic leukemia.
November 12, 2020
Christopher Pleyer, MD, discusses the phase 2 study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.